EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives

Silvia Carrara, Michele Bevere, Donatella Delle Cave, Manuel Gentiluomo, Irene Esposito, Claudio Luchini

Digestive and Liver Disease · 2026

DOI: 10.1016/j.dld.2026.03.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Silvia Carrara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Department of Gastroe…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Italian Association for Cancer Research, Italian Foundation for Research on Pancreatic Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is usually diagnosed at advanced stages. The diagnosis of PDAC is established through pancreatic cytology/tissue biopsy, most commonly obtained under endoscopic ultrasound-guidance. Although this approach is generally safe and accurate for the histological diagnosis, maintaining/obtaining material for additional molecular analysis may be challenging. Thus, there is growing interest in minimally invasive approaches capable of providing molecular information without necessarily requiring tissue sampling. Liquid biopsy (LB) represents a significant advancement in this regard, being a minimally invasive tool for biomarker analysis and with the potential to improve patient management at various levels. The most relevant biomarkers that LB can detect are circulating tumor cells, cell-free DNA, circulating miRNA, and extracellular vesicles. Integrating LB into the clinical workflow may improve the diagnosis, prognosis, and monitoring of the disease, even for patients affected by PDAC and with potential implications on early detection approaches. Despite significant progress, no LB assay is yet validated for routine PDAC management; however, growing evidence suggests that multimodal LB integration may soon reshape diagnostic and surveillance strategies. Here we provide a comprehensive overview on liquid biopsy in pancreatic cancer, presenting its current progress, limitations, and future perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansLiquid BiopsyNeoplastic Cells, CirculatingPrognosisMicroRNAsCirculating Tumor DNA

Stichwörter der Autor:innen

CTCsCirculating tumor cellsLiquid biopsyPDACPancreatic cancerPancreatic ductal adenocarcinomacfDNA

Substanzen

Biomarkers, TumorMicroRNAsCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Department of Gastroenterology, 20089 Rozzano, Milan, Italy.
  • ARC-Net Applied Research on Cancer Center, University of Verona, 37134 Verona, Italy.
  • Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso', National Research Council CNR, 80131 Naples, Italy.
  • Department of Biology, University of Pisa, 56126 Pisa, Italy.
  • Institute of Pathology, Heinrich-Heine University and University Hospital of Düsseldorf, 40225 Düsseldorf, Germany.
  • ARC-Net Applied Research on Cancer Center, University of Verona, 37134 Verona, Italy; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, 37134 Verona, Italy. Electronic address: cla…

Förderung

  • Ministero dell'Università e della Ricerca
  • Italian Association for Cancer Research
  • Italian Foundation for Research on Pancreatic Diseases

Zitieren

APA

Carrara, S., Bevere, M., Delle Cave, D., Gentiluomo, M., Esposito, I., & Luchini, C. (2026). Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.03.002

Vancouver

Carrara S, Bevere M, Delle Cave D, Gentiluomo M, Esposito I, Luchini C. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.03.002

BibTeX
@article{Carrara2026,
  author = {Carrara, Silvia and Bevere, Michele and Delle Cave, Donatella and Gentiluomo, Manuel and Esposito, Irene and Luchini, Claudio},
  title = {Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2026.03.002}
}
Kostenlos starten →